Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial

Recruiting now · Phase 2

Conditions studied: Hepatocellular Carcinoma

In brief

Atezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for those patients is still unknown. This phase 2 clinical trial aims to investigate the objective response rate for unresectable advanced hepatocellular carcinoma.

Key facts

Study ID

NCT05751343

Run by

Sun Yat-sen University

People needed

55

Starts

2023-03-09

Expected to finish

2025-12-30

Last updated by the study team

2025-11-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• (a) patients were diagnozied with unresectable advanced-stage HCC,
• (b) Child-Pugh A or B liver function;
• (d) Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
• (e) adequate hematologic blood counts (white blood cell count >3ⅹ109/L, absolute neutrophil count >1.5ⅹ109/L, platelet count >10ⅹ109/L, hemoglobin concentration >85 g/L);

You may not qualify if…

• (a) severe underlying cardiac, pulmonary, or renal diseases;
• (b) history of a second primary malignant tumor;
• (c) contraindication to either atezolizumab and bevacizumab.

Where it is running

• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.